UA-93693832-1skip to primary navigationskip to content

Metrion Biosciences announces two new partnerships to strengthen their Ion Channel Drug Discovery Service

Metrion Biosciences is currently pursuing a strategy to actively strengthen capabilities via collaborations with carefully selected, high quality partner companies. Two recent press releases demonstrate the value of this strategy.

Metrion Biosciences and Concept Life Sciences Introduce Integrated Ion Channel Drug Discovery Service. Metrion and Concept partner to provides a complete managed package of contract research services to support small molecule ion channel drug discovery, from initial screening to development candidate. Combined with Metrion’s recently announced alliance with Assay.Works, this partnership provides an ’end to end‘ service for pharmaceutical clients wishing to conduct new ion channel targeted drug discovery projects. For full press release click here

Metrion Biosciences and Assay.Works announce collaboration to enhance ion channel drug discovery capability. As a result of the collaboration, Metrion now is now able to offer its clients access to High Throughput Screening (HTS) and Assay.Works assay validation technologies, including 384-well format screening and compound handling facilities. In addition the relationship brings Metrion a library of 74,000 small molecules and a catalogue of ‘Assay.Ready’ cell lines for use in primary screening and selectivity assays. In turn Assay.Works and their clients can access Metrion’s extensive ion channel target know-how, electrophysiology based assay services, CiPA compliant cardiac safety profiling, and expanding range of phenotypic and translational assays in the cardiac and neuroscience fields. For full press release click here





























        See Affiliated Companies